This novel regulatory axis involving PXN-AS1, miR-635, GS, mTOR, and Cyclin D-CDK4/6 contributes to the development of drug resistance in CML patients. Here, CDK4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.